UY38412A - Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma - Google Patents

Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma

Info

Publication number
UY38412A
UY38412A UY0001038412A UY38412A UY38412A UY 38412 A UY38412 A UY 38412A UY 0001038412 A UY0001038412 A UY 0001038412A UY 38412 A UY38412 A UY 38412A UY 38412 A UY38412 A UY 38412A
Authority
UY
Uruguay
Prior art keywords
composition
preparing
same
reduced dose
combined vaccine
Prior art date
Application number
UY0001038412A
Other languages
English (en)
Inventor
Rakesh Kumar
Jit Sharma Inder
Semburakkiannan Kilvani Jaganathan
Manohar Doddapaneni
Vyankatrao Shitole Anil
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of UY38412A publication Critical patent/UY38412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a una composición inmunogénica completamente líquida que comprende una combinación de antígenos/inmunógenos. La composición inmunogénica comprende una cantidad óptima de antígenos/inmunógenos para conferir protección contra numerosas enfermedades. La composición exhibe mejor inmunogenicidad y estabilidad. También se describe un proceso para preparar la composición de vacuna.
UY0001038412A 2018-10-12 2019-10-10 Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma UY38412A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201821038850 2018-10-12

Publications (1)

Publication Number Publication Date
UY38412A true UY38412A (es) 2020-04-30

Family

ID=68542707

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038412A UY38412A (es) 2018-10-12 2019-10-10 Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma

Country Status (22)

Country Link
US (1) US12090195B2 (es)
EP (1) EP3863665A1 (es)
JP (1) JP7478144B2 (es)
KR (1) KR102822878B1 (es)
CN (1) CN113164577B (es)
AR (1) AR116631A1 (es)
AU (1) AU2019359564B2 (es)
BR (1) BR112021006707A2 (es)
CA (1) CA3115803A1 (es)
CO (1) CO2021004556A2 (es)
EA (1) EA202190778A1 (es)
GE (2) GEP20247684B (es)
JO (1) JOP20190242B1 (es)
MD (1) MD4890C1 (es)
MX (1) MX2021004233A (es)
PE (1) PE20211648A1 (es)
PH (1) PH12021550812A1 (es)
SG (1) SG11202103622SA (es)
TW (1) TW202034948A (es)
UY (1) UY38412A (es)
WO (1) WO2020075184A1 (es)
ZA (1) ZA202103154B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004233A (es) * 2018-10-12 2021-08-16 Serum Inst Of India Private Ltd Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma.
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CN112316126B (zh) * 2020-10-29 2021-08-13 武汉生物制品研究所有限责任公司 一种氢氧化铝佐剂吸附百日咳菌毛(Fim)抗原制品的制备方法
CN116355083B (zh) * 2023-05-30 2023-09-08 国药中生生物技术研究院有限公司 特异性结合脊髓灰质炎病毒i型抗原的抗体
WO2025252927A1 (en) * 2024-06-07 2025-12-11 The Provost, Fellows, Foundation Scholars & The Other Members Of Board, Of The College Of The Holy & Undivided Trinity Of Queen Elizabeth Near Dublin Vaccine compositions and methods and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69018990T2 (de) 1989-07-14 1995-12-14 Praxis Biolog Inc Stabile interleukine enthaltende impfstoffzusammensetzungen.
FI945483A7 (fi) 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
WO1998034594A1 (en) 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
CA2303105A1 (en) 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1004314A1 (fr) 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
US20040258700A1 (en) * 2003-06-23 2004-12-23 Frimann Tine Holland Vaccine formulation with a preservative
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0616226D0 (en) 2006-08-15 2006-09-27 Novartis Ag Processes
US8945582B2 (en) * 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
CN101835797A (zh) * 2007-11-23 2010-09-15 上海泽润生物科技有限公司 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
EP3459562B1 (en) 2011-01-05 2024-03-20 Bharat Biotech International Limited A combination heptavalent vaccine
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
EA037283B1 (ru) 2015-09-16 2021-03-04 ЭлДжи КЕМ, ЛТД. Комбинированная вакцинная композиция для многократного дозирования
SG11201900365WA (en) 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
GEP20227386B (en) * 2017-07-18 2022-06-10 Serum Institute Of India Pvt Ltd Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
MX2021004233A (es) * 2018-10-12 2021-08-16 Serum Inst Of India Private Ltd Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma.

Also Published As

Publication number Publication date
GEAP202415627A (en) 2024-05-13
MD20210028A2 (ro) 2021-11-30
SG11202103622SA (en) 2021-05-28
WO2020075184A1 (en) 2020-04-16
KR102822878B1 (ko) 2025-06-20
JOP20190242B1 (ar) 2025-10-01
GEP20247684B (en) 2024-10-28
MD4890B1 (ro) 2024-04-30
ZA202103154B (en) 2022-03-30
PH12021550812A1 (en) 2021-11-08
AU2019359564B2 (en) 2026-02-05
JP7478144B2 (ja) 2024-05-02
CN113164577A (zh) 2021-07-23
JOP20190242A1 (ar) 2020-04-12
TW202034948A (zh) 2020-10-01
AR116631A1 (es) 2021-05-26
MD4890C1 (ro) 2024-11-30
BR112021006707A2 (pt) 2021-07-27
US20210346483A1 (en) 2021-11-11
MX2021004233A (es) 2021-08-16
EP3863665A1 (en) 2021-08-18
PE20211648A1 (es) 2021-08-24
CN113164577B (zh) 2024-06-18
CA3115803A1 (en) 2020-04-16
EA202190778A1 (ru) 2021-08-05
JP2022502469A (ja) 2022-01-11
CO2021004556A2 (es) 2021-04-30
AU2019359564A1 (en) 2021-06-03
US12090195B2 (en) 2024-09-17
KR20210091158A (ko) 2021-07-21

Similar Documents

Publication Publication Date Title
UY38412A (es) Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
MX2023000211A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
MX2019007349A (es) Vacuna combinada para cerdos.
HRP20140488T1 (hr) Cjepivo protiv influence
CL2015002513A1 (es) Vacuna acelular contra pertussis
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
BR112022004488A2 (pt) Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos
MX2017000154A (es) Sistema de rinovacunacion de la vacuna contra la influenza.
CO2025007834A2 (es) Composiciones inmunogénicas y métodos para provocar una respuesta inmunitaria contra clostridioides (clostridium) difficile
RU2018131243A (ru) Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
MA42317B2 (fr) Composition de vaccin combinée pour administration multiple
AR117191A1 (es) Composiciones inmunogénicas
CO2025003056A2 (es) Proteína g antirrábica y sus usos
BR112012014689A2 (pt) composição de vacina
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
AR103030A1 (es) Composición inmunógena
CL2022000086A1 (es) Vacunas contra ehrlichia y composiciones inmunogénicas
CU20200097A7 (es) Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b
AR121752A1 (es) VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
AR131340A1 (es) Composiciones inmunogénicas y métodos para provocar una respuesta inmunitaria contra clostridioides (clostridium) difficile